BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 03/17/2014
Entire Document
 
6

 
 
BioLineRx Ltd.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
 
   
Note
   
Year ended December 31,
   
Convenience translation into USD
 
         
2011
   
2012
   
2013
   
2013
 
         
NIS in thousands
   
In thousands
 
                               
RESEARCH AND DEVELOPMENT EXPENSES, NET
    14d       (42,623 )     (64,304 )     (44,057 )     (12,692 )
SALES AND MARKETING
EXPENSES
    14e       (3,308 )     (3,227 )     (4,101 )     (1,182 )
GENERAL AND ADMINISTRATIVE EXPENSES
    14f       (12,722 )     (14,026 )     (13,225 )     (3,810 )
                                         
OPERATING LOSS
            (58,653 )     (81,557 )     (61,383 )     (17,684 )
NON-OPERATING INCOME, NET
    14g       -       3,958       4,191       1,207  
FINANCIAL INCOME
    14h       12,730       8,819       2,600       749  
FINANCIAL EXPENSES
    14i       (4,263 )     (7,490 )     (6,846 )     (1,972 )
                                         
NET LOSS AND COMPREHENSIVE LOSS
            (50,186 )     (76,270 )     (61,438 )     (17,700 )
                                         
           
NIS
   
USD
 
LOSS PER ORDINARY SHARE - BASIC
    11       (0.41 )     (0.45 )     (0.27 )     (0.08 )
LOSS PER ORDINARY SHARE - DILUTED
    11       (0.41 )     (0.45 )     (0.27 )     (0.08 )